Shionogi Pharmaceutical Co., Ltd., headquartered in Osaka, has applied to the Ministry of Health, Labor and Welfare for approval of a new coronavirus drug.
If approved, it will be the first new corona drug developed by a domestic pharmaceutical company that can be used in the mild stage.
Shionogi Pharmaceutical Co., Ltd. announced on the 25th that it has applied for approval from the Ministry of Health, Labor and Welfare for the new corona drug for mildly ill patients.
According to this, the company reportedly to 428 patients aged 12 years or older with mild to moderate new coronaviruses, mainly during the period when the infection of the Omicron strain spread, once a day within 5 days after the infection was confirmed. We analyzed data from clinical trials administered daily.
As a result, less than 10% of people detected the infectious virus after receiving the drug three times, which was lower than the group taking the fake drug.
He also said that he had confirmed improvement in respiratory symptoms such as runny nose, stuffy nose, sore throat, cough, and shortness of breath, and had mild side effects.
The company is also proceeding with a final stage clinical trial targeting about 2,000 people, but since it was found to be highly effective in the middle stage, it is said that it was the first in the world to apply for approval in Japan.
"Lagebrio" and "Pakirovid Pack" developed by overseas pharmaceutical companies have been approved in Japan for the new corona drug that can be used in the mild stage, but if Shionogi's drug is approved, it will be domestic. This is the first and third type of pharmaceutical company.
According to the company, it plans to produce 1 million people by the end of next month and more than 10 million people a year after April.